# Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

> **NCT00599287** · PHASE3 · TERMINATED · sponsor: **UMC Utrecht** · enrollment: 80 (estimated)

## Conditions studied

- Delirium

## Interventions

- **DRUG:** Haloperidol
- **DRUG:** Methylphenidate
- **DRUG:** Rivastigmine

## Key facts

- **NCT ID:** NCT00599287
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 80 (ESTIMATED)
- **Why stopped:** Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent.
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00599287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00599287, "Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00599287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*